All In Biotech

Drug Trial Radar · NCT03533283

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

211

Actual

Start

May 8, 2018

Primary completion

Oct 22, 2026

Study completion Oct 22, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.

Conditions

  • Non-Hodgkins Lymphoma

Interventions

  • GlofitamabDrug

    Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.

  • AtezolizumabDrug

    Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).

  • ObinutuzumabDrug

    Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.

  • TocilizumabDrug

    Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).

  • Polatuzumab VedotinDrug

    Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).

  • 89Zr-Df-IAB22M2CDrug

    Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Objective Response Rate (ORR) as Measured by Independent Review Committee (IRC)Time frame: Baseline until the end of treatment (13 to 14 months), then ever 3 months until end of study visit (to occur within 4 weeks of disease progression)
  2. Dose Limiting Toxicities (DLTs)Time frame: Atezolizumab Arm: During DLT period of 21 days (or up to 42 days in the case of cycle delay), starting on Day 1, Cycle 2; Polatuzumab Vedotin Arm: During 5-week DLT period starting Cycle 1, Day 8

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Novant Health Cancer Institute

    Charlotte, North Carolina

  • UZ Gent

    Ghent, Belgium

  • Aarhus Universitetshospital Skejby

    Aarhus N, Denmark

  • Rigshospitalet

    København Ø, Denmark

  • Odense Universitetshospital

    Odense C, Denmark

  • Hadassah Ein Karem Hospital

    Jerusalem, Israel

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale

    Naples, Campania, Italy

  • Policlinico S.Orsola-Malpighi

    Bologna, Emilia-Romagna, Italy

  • Asst Papa Giovanni Xxiii

    Bergamo, Lombardy, Italy

  • Fond. IRCCS Istituto Nazionale Tumori

    Milan, Lombardy, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Duran i Reynals

    Barcelona, Spain

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • The HOPE Clinical Trials Unit

    Leicester, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.